Nuformix PLC Loan Conversion (1024A)
24 Mayo 2019 - 1:00AM
UK Regulatory
TIDMNFX
RNS Number : 1024A
Nuformix PLC
24 May 2019
Nuformix plc
("Nuformix" or the "Company")
Conversion of Loan Note
Cambridge, UK, 16 May 2019: Nuformix, the pharmaceutical
development company using cocrystal technology to unlock the
therapeutic potential of approved small molecule drugs, announces
that it has received notice from Mr Alan Miller in accordance with
the Convertible Loan Agreement dated 18 April 2017 (as amended) to
convert the outstanding loan of GBP200,000 with accrued interest
("Loan"). In accordance with the notice the Company has today
issued 8,716,512 ordinary shares fully paid and 8,716,512 warrants
to subscribe for ordinary shares at 2.75p per share exercisable at
any time for 60 months to Mr Miller in settlement of the Loan.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer
Tel: +44 (0)1223 423667
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio of granted patents covering
cocrystal forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CONFMGZKKDMGLZG
(END) Dow Jones Newswires
May 24, 2019 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024